Inaba: Real-world data concerning the efficacy of molnupiravir in patients vaccinated against COVID-19 during the Omicron surge in Japan

Real-world data concerning the efficacy of molnupiravir in patients vaccinated against COVID-19 during the Omicron surge in Japan

Inaba et al., Research Square, doi:10.21203/rs.3.rs-2451986/v1 (Preprint)

Inaba et al., Real-world data concerning the efficacy of molnupiravir in patients vaccinated against COVID-19 during the.., Research Square, doi:10.21203/rs.3.rs-2451986/v1 (Preprint)

Jan 2023 Source PDF

Twitter
Facebook

All Studies Meta

Retrospective 294 consecutive patients in Japan, showing higher risk of hospitalization/death with molnupiravir, without statistical significance.

Concerns have been raised that the mutagenic mechanism of action may create dangerous variants or cause cancer [Hadj Hassine, Swanstrom]. See [twitter.com] for analysis of a variant potentially created by molnupiravir.

1. Hadj Hassine et al., Viruses, doi:10.3390/v14040841, Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity, https://www.mdpi.com/1999-4915/14/4/841.

2. Swanstrom et al., Science, doi:10.1126/science.abn0048, Lethal mutagenesis as an antiviral strategy, https://www.science.org/doi/10.1126/science.abn0048.

3. twitter.com, https://twitter.com/LongDesertTrain/status/1597353291868155906.

Important missing comments or errors? Let us know.

risk of death, 58.3% lower, RR 0.42, p = 1.00, treatment 0 of 84 (0.0%), control 1 of 210 (0.5%), NNT 210, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).

risk of death/hospitalization, 127.0% higher, RR 2.27, p = 0.22, treatment 5 of 84 (6.0%), control 8 of 210 (3.8%), odds ratio converted to relative risk, day 28.

risk of hospitalization, 127.0% higher, RR 2.27, p = 0.22, treatment 5 of 84 (6.0%), control 8 of 210 (3.8%), odds ratio converted to relative risk, day 28.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Inaba et al., 15 Jan 2023, retrospective, Japan, preprint, 9 authors.

All Studies All Outcomes Submit Updates or Corrections

This Paper Molnupiravir All

Download Image

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit